Skip to main content

Closed

XLO: Xilio Therapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+589.9% / yr

Operating margin-79.0%

ROIC-34.7%

Financially safe

Stretched

Debt / equity0.09×

Interest coverage0.0×

Current ratio3.59×

Xilio Therapeutics, Inc.

XLONASDAQ Global Select·USD·Closed

Xilio Therapeutics, Inc.

XLONASDAQ·USD·Closed

$9.11

+0.29%

$9.11

+$0.03 (0.29%)

52W Range

42thpctl

Volume

0.22×avg

Mkt Cap

59.90MUSD

P/E

-1.7TTM

Div Yield

–ann

52W Range

42thpctl

Volume

0.22×avg

Market Cap

59.90MUSD

P/E Ratio

-1.7TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings